Showing 4061-4070 of 6035 results for "".
- Vabysmo Prefilled Syringe (PFS) Approved in the EUhttps://modernod.com/news/vabysmo-prefilled-syringe-pfs-approved-in-the-eu-for-three-retinal-conditions/2482582/The European Medicines Agency (EMA) has approved Roche's Vabysmo (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion
- Viridian Announces Topline Results from Veligrotug Phase 3 Trial in Patients with Chronic TEDhttps://modernod.com/news/viridian-announces-positive-topline-results-from-veligrotug-phase-3-trial-in-patients-with-chronic-thyroid-eye-disease/2482580/Viridian Therapeutics announced positive topline data from the THRIVE-2 phase 3 clinical trial of veligrotug (veli), an intravenously (IV) delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). “We are extremely
- Atsena Completes Dosing in Part A of Phase 1/2 Trial Evaluating Gene Therapy to Treat X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-completes-dosing-in-part-a-of-phase-12-trial-evaluating-gene-therapy-atsn-201-to-treat-x-linked-retinoschisis/2482579/Atsena Therapeutics announced dosing has been completed in Part A of the LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201, a best-in-class gene therapy product candidate, leverages AAV.S
- Tenpoint and Visus Complete Mergerhttps://modernod.com/news/tenpoint-and-visus-complete-merger/2482576/Tenpoint Therapeutics and Visus Therapeutics announced the completion of their merger. “As we relaunch Tenpoint as a combined entity with Visus, we are excited to lead with a robust ophthalmology pipeline, starting with Brimochol PF, a near-term therapeutic medicine for presbyopia
- Bausch + Lomb Acquires Elios Vision to Bolster Glaucoma Surgical Portfoliohttps://modernod.com/news/bausch-lomb-acquires-elios-vision-to-bolster-glaucoma-surgical-portfolio/2482575/Bausch + Lomb announced that an affiliate has acquired Elios Vision, developer of the ELIOS procedure, a minimally invasive glaucoma surgery (MIGS) procedure using an excimer laser. Financial terms of the deal were not disclosed. According to B+
- The Centre for Eye and Vision Research and SCOPE Health Partner to Innovate Ocular Surface Disease Solutionshttps://modernod.com/news/the-centre-for-eye-and-vision-research-and-scope-health-partner-to-innovate-ocular-surface-disease-solutions/2482571/The Centre for Eye and Vision Research (CEVR) and SCOPE Health Inc. have signed a Memorandum of Understanding (MoU) to collaborate on technologies to treat dry eye disease and other ocular surface conditions. The partnership aims to address unmet needs in eye care by leveraging SCOPE&rs
- Outlook Therapeutics Receives NICE Recommendation of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-receives-nice-recommendation-for-lytenava-as-a-treatment-for-wet-amd/2482567/The UK’s National Institute for Health and Care Excellence (NICE) has recommended Lytenava (bevacizumab gamma) as an option for the treatment of wet AMD in adults. This marks the first positive reimbursement decision for Lytenava worldwide and supports its commercializat
- Galimedix Begins Phase 1 Clinical Trial of Oral GAL-101 for Neuroprotective Treatmenthttps://modernod.com/news/galimedix-therapeutics-begins-phase-1-clinical-trial-of-oral-gal-101-for-neuroprotective-treatment/2482565/Galimedix Therapeutics announced the first volunteers have been dosed in the company’s phase 1 study of oral GAL-101, an amyloid beta (Aβ) aggregation modulator. This trial is designed to assess the safety, tolerability, and pharmacokinetics of single and multiple ascending doses
- EyePoint Announces First Patient Dosed in Phase 3 LUCIA Trial of Duravyu for Wet AMDhttps://modernod.com/news/eyepoint-announces-first-patient-dosed-in-phase-3-lucia-trial-of-duravyu-for-wet-amd/2482563/EyePoint Pharmaceuticals announced that the first patient has been dosed in the LUCIA trial. This is the second global phase 3 clinical trial evaluating Duravyu (formerly EYP-1901), a sustained-delivery therapy for treating wet age-related macular degeneration (AMD). Duravyu is an inves
- Nicole Skibinski Appointed Chief Executive Officer of Fluorescene Mediahttps://modernod.com/news/nicole-skibinski-appointed-chief-executive-officer-of-fluorescene-media/2482562/Nicole Skibinski was appointed Chief Executive Officer of Fluorescene Media, which aims to help optometry professionals connect, learn, and thrive. Ms. Skibinski has more than 20 years of leadership in the eye care and health care industries, with experience in